Diuretic effects of sodium–glucose cotransporter 2 inhibitor in patients with type 2 diabetes mellitus and heart failure
Authors:
- 1 December 2015
- journal article
- Published by Elsevier in International Journal of Cardiology
- Vol. 201, 1-3
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Blood pressure effects of sodium–glucose co-transport 2 (SGLT2) inhibitorsJournal of the American Society of Hypertension, 2014
- Novel Diuretic Strategies for the Treatment of Heart Failure in JapanCirculation Journal, 2014
- Dapagliflozin a glucose‐regulating drug with diuretic properties in subjects with type 2 diabetesDiabetes, Obesity and Metabolism, 2013
- Managing Hyperkalemia Caused by Inhibitors of the Renin–Angiotensin–Aldosterone SystemNew England Journal of Medicine, 2004
- Influence of diabetes mellitus on heart failure risk and outcomeCardiovascular Diabetology, 2003
- Diabetes mellitus and congestive heart failureEuropean Heart Journal, 1999
- Incidence, clinical and etiologic features, and outcomes of advanced chronic heart failure: the EPICAL studyJACC, 1999
- Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD).Circulation, 1990
- Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics.Heart, 1987